Disease management
The AI-powered app allows for remote monitoring of common Parkinson's disease symptoms such as bradykinesia, tremor and dyskinesia via an Apple Watch.
The company will use the funds to advance the study of its neuromodulation device intended to treat Alzheimer's disease.
A study published in The New England Journal of Medicine found a closed-loop control system kept children's glucose levels in the target range longer than standard care.
The program will be available through Amwell in the second half of 2023.
The company will use the funds to circulate its ArteraAI Prostate Test and to develop tests to support individualized therapy options for other cancers.
The funds will be used to accelerate the adoption of the platform's applied behavior analysis-focused tools.
BlueRock Therapeutics will utilize Rune Labs' StriveStudy clinical trial platform and FDA-cleared Apple Watch data-collection tool to monitor Parkinson's disease.
The wearable device directly measures respiration to predict deterioration in COPD patients.
Viz.ai also announced an agreement with Bristol Myers Squibb to identify patients with hypertrophic cardiomyopathy.
Also, medical device unicorn Molbio has taken a 70% stake in digital x-ray manufacturer Prognosys.